Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (1190)	12/4/1999 12:41:00 PM
From: William Partmann	Read Replies (1) \| Respond to of 1686

BGEN: Presentation of Amevive Phase II Data; Phase III Initiated Salomon Smith Barney Friday, December 03, 1999 -------------------------------------------------------------------------------- --SUMMARY:--Biogen--Biotechnology Today, at a psoriasis meeting in London, Biogen presented positive phase II data for Amevive in patients with moderate-to-severe plaque psoriasis. This was expected news. A total of 229 pts were randomized to weekly IV bolus injections of Amevive (0.025mg/kg, 0.075mg/kg or 0.15mg/kg) or placebo for 12 weeks, followed by 12 weeks of observation. Patients on the two higher doses had a statistically significant clearance or almost clearance of psoriasis 2 weeks after receiving their last dose. The drug was shown to be safe and well-tolerated. No adverse events were observed. Biogen also announced that it has begun phase III trials for Amevive. We expect regulatory filing by end of 2001 and launch in 2H2002. --EARNINGS PER SHARE-------------------------------------------------------- FYE 1 Qtr 2 Qtr 3 Qtr 4 Qtr Year Actual 12/98 EPS $0.18A $0.20A $0.24A $0.27A $0.90A Previous 12/99 EPS $0.29A $0.34A $0.39A $0.43E $1.45E Current 12/99 EPS $0.29A $0.34A $0.39A $0.43E $1.45E Previous 12/00 EPS $N/A $N/A $N/A $N/A $1.80E Current 12/00 EPS $N/A $N/A $N/A $N/A $1.80E Previous 12/01 EPS $N/A $N/A $N/A $N/A $2.20E Current 12/01 EPS $N/A $N/A $N/A $N/A $2.20E Footnotes: --FUNDAMENTALS-------------------------------------------------------------- Current Rank........:2S Prior:No Change Price (12/2/99).....:$77.00 P/E Ratio 12/99.....:53.1x Target Price..:$77.00 Prior:No Change P/E Ratio 12/00.....:42.8x Proj.5yr EPS Grth...:25.0% Return on Eqty 98...:22.1% Book Value/Shr(99)..:4.88 LT Debt-to-Capital(a)N/A% Dividend............:$N/A Revenue (99)........:773.00mil Yield...............:N/A% Shares Outstanding..:149.9mil Convertible.........:No Mkt. Capitalization.:11542.3mil Hedge Clause(s).....: Comments............:(a) Data as